MTOR and prostate cancer: Comforting our data, a relationship between Tau and the PI3K/Akt pathway has been previously proposed since the down-regulation of Tau in Docetaxel-resistant prostate cancer cells rescued drug resistance by inhibiting the PI3K/Akt/mTOR signaling pathway [13].